Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
holding | TRDA | Series A Preferred Stock | Oct 28, 2021 | Common Stock | 2.5M | See Footnote | F1, F2 | |||||||
holding | TRDA | Series B Preferred Stock | Oct 28, 2021 | Common Stock | 318K | See Footnote | F1, F2 |
Id | Content |
---|---|
F1 | Each share of Series A Preferred Stock is convertible into common stock on a 1-for-7.235890014 basis into the number of shares of Common Stock shown in column 3 at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. Each share of Series B Preferred Stock is convertible into Common Stock on a 1-for-7.235890014 basis into the number of shares of Common Stock shown in column 3 at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Series A Preferred Stock and Series B Preferred Stock have no expiration date. |
F2 | Represents shares held by Roche Finance Ltd ("Roche Finance"). Roche Finance is a wholly owned subsidiary of Roche Holding Ltd ("Roche Holding"), a Swiss corporation whose shares are traded on the SIX Swiss Exchange. Roche Holding is the indirect beneficial owner of these securities of the Issuer. This Form 3 shall not be deemed an admission that any reporting person or other person is a beneficial owner of any securities of the Issuer for any purpose, other than the securities reported in this Form 3. |
Exhibit 24 - Power of Attorney